[1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022,72:7-33.
|
[2] |
Wang W, Kandimalla R, Huang H, et al. Molecular subtyping of colorectal cancer: recent progress, new challen-ges and emerging opportunities[J]. Semin Cancer Biol, 2019, 55:37-52.
|
[3] |
Rizzo G, Bertotti A, Leto SM, et al. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer[J]. J Exp Clin Cancer Res, 2021,40:178. doi: 10.1186/s13046-021-01970-2.
|
[4] |
Voulgarelis D, Bulusu KC, Yates JWT. Comparison of classical tumour growth models for patient derived and cell-line derived xenografts using the nonlinear mixed-effects framework[J]. J Biol Dyn, 2022,16:160-185.
|
[5] |
Costa B, Estrada MF, Barroso MT, et al. Patient-derived avatars from digestive cancers for anti-cancer therapy screening[J]. Curr Protoc, 2022, 2:e415. doi: 10.1002/cpz1.415.
|
[6] |
Guo S, Gao S, Liu R, et al. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer[J]. FASEB J, 2019,33:873-884.
|
[7] |
Abdolahi S, Ghazvinian Z, Muhammadnejad S, et al. Patient-derived xenograft (PDX) models, applications and challenges in cancer research[J]. J Transl Med, 2022,20:206.doi: 10.1186/s12967-022-03405-8.
|
[8] |
Ji X, Chen S, Guo Y, et al. Establishment and evaluation of four different types of patient-derived xenograft models[J]. Cancer Cell Int, 2017,17:122.doi: 10.1186/s12935-017-0497-4.
|
[9] |
Huang L, Wang J, Fang B, et al. CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts[J]. Sci Rep, 2022,12:12984.doi: 10.1038/s41598-022-16933-6.
|
[10] |
Zhang H, Yuan L, Liu L, et al. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab[J]. BMC Cancer, 2020,20:416.doi: 10.1186/s12885-020-06909-y.
|
[11] |
Cheng Y, Qin SK, Li J, et al. A multicenter clinical study: personalized medication for advanced gastrointes-tinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX)[J]. J Cancer Res Clin Oncol, 2022,148:673-684.
|
[12] |
Lee S, Pyo DH, Sim WS, et al. Early and long-term outcomes after propofol-and sevoflurane-based anesthesia in colorectal cancer surgery: A retrospective study[J]. J Clin Med, 2022,11:2648.doi: 10.3390/jcm11092648.
|
[13] |
Kang FC, Wang SC, So EC, et al. Propofol may increase caspase and MAPK pathways, and suppress the Akt pathway to induce apoptosis in MA 10 mouse Leydig tumor cells[J]. Oncol Rep, 2019,41:3565-3574.
|
[14] |
Zhang Y, Ding X, Miao C, et al. Propofol attenuated TNF-α-modulated occludin expression by inhibiting Hif-1α/VEGF/VEGFR-2/ERK signaling pathway in hCMEC/D3 cells[J]. BMC Anesthesiol, 2019,19:127.doi: 10.1186/s12871-019-0788-5.
|
[15] |
王玉龙, 滕文彬, 单跃, 等. HIF-1α激动或拮抗剂对脓毒症大鼠肠道黏膜通透性的影响[J]. 基础医学与临床, 2021, 41: 1618-1623.
|